EUVIMEDEUVIMED entdecken
Open Access

[ 18 F]Florzolotau PET for the Differential Diagnosis of Parkinsonism in Patients with Suspected 4-Repeat Tauopathies

Joachim Brumberg, Nils Schröter, Ganna Blazhenets, M Aymen Omrane, Christian Volz, Cornelius Weiller, Michel Rijntjes, Lars Frings, Sabine Hellwig, Wolfgang H Jost, Philipp T Meyer

Journal of Nuclear Medicine · 2025-06 · 66 (6) · 926-931

DOI: 10.2967/jnumed.124.268956 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 17.04.2025. Verfasst von Joachim Brumberg und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Medical Center, University of Freiburg, Freiburg, Germany; joachim.brumberg@uniklinik-freiburg.de. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Tauopathies, Parkinsonian Disorders, Carbolines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The second-generation tau radioligand [18F]florzolotau is a promising biomarker for 4-repeat (4R) tauopathies such as progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), which are difficult to disentangle clinically. Prior studies evaluating the diagnostic accuracy of [18F]florzolotau PET focused on highly selected patient populations (e.g., PSP-Richardson syndrome or amyloid-β-negative corticobasal syndrome). The present study assesses the diagnostic performance of [18F]florzolotau PET in conjunction with visual reads in a real-world clinical cohort.

Methods

Ninety-four consecutive patients with parkinsonism and possible 4R tauopathy undergoing [18F]florzolotau PET for differential diagnosis were enrolled and retrospectively analyzed. The interdisciplinary consensus diagnosis based on comprehensive clinical and imaging data (most notably, [18F]FDG PET) served as the reference standard. [18F]florzolotau PET was assessed visually using predefined 4R-like and Alzheimer disease (AD)-like binding patterns (on a 4-point scale). In addition, 4R-like cases were rated with respect to the cortical-subcortical gradient of 4R-like binding. The diagnostic performance was assessed by receiver operating characteristic (ROC) analyses.

Results

The 4R-like pattern was more prevalent and more strongly expressed (84.3%, mean score, 2.0 ± 1.1) in patients with a consensus diagnosis of PSP/CBD (joint diagnostic group of clinically likely 4R tauopathies) than in all other groups (11.6%, 0.26 ± 0.75, P < 0.0001). An AD-like pattern was present in all patients with a consensus diagnosis of AD (100%, 2.5 ± 0.9) and at high frequency, albeit with lower magnitude, in all other patient groups (67.4%, 1.2 ± 1.1, P < 0.01). ROC analysis for the 4R-like pattern (PSP/CBD vs. all other patients) yielded an area under the ROC curve (AUC) of 0.87 (sensitivity, 84.3%; specificity, 88.4%). The diagnostic performance of [18F]florzolotau PET did not change when also considering the AD-like pattern (AUC, 0.88; logistic regression, factor AD-like pattern; P = 0.53) or excluding all cases with AD (AUC, 0.86). The presence of corticobasal syndrome in patients with 4R-like binding was strongly associated with preferentially cortical binding (AUC, 0.89).

Conclusion

Based on a real-world population of patients with parkinsonism, we demonstrate that simple visual evaluation of [18F]florzolotau PET by an a priori-defined 4R-like binding pattern allows highly accurate identification of patients with a consensus diagnosis of PSP/CBD. Thus, [18F]florzolotau PET is a promising biomarker for differential diagnosis of neurodegenerative parkinsonian syndromes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyTauopathiesParkinsonian DisordersCarbolinesHumansMaleFemaleDiagnosis, DifferentialAgedMiddle AgedRetrospective Studies

Stichwörter der Autor:innen

4R tauopathyparkinsonian syndrometau PET

Substanzen

Carbolines7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Medical Center, University of Freiburg, Freiburg, Germany; joachim.brumberg@uniklinik-freiburg.de.
  • Department of Neurology and Neurophysiology, Medical Center, University of Freiburg, Freiburg, Germany.
  • Department of Nuclear Medicine, Medical Center, University of Freiburg, Freiburg, Germany.
  • Department of Psychiatry and Psychotherapy, Medical Center, University of Freiburg, Freiburg, Germany; and.
  • Parkinson-Klinik Ortenau, Wolfach, Germany.

Zitieren

APA

Brumberg, J., Schröter, N., Blazhenets, G., Omrane, M. A., Volz, C., Weiller, C., Rijntjes, M., Frings, L., Hellwig, S., Jost, W. H., & Meyer, P. T. (2025). [ 18 F]Florzolotau PET for the Differential Diagnosis of Parkinsonism in Patients with Suspected 4-Repeat Tauopathies. Journal of Nuclear Medicine, 66(6), 926-931. https://doi.org/10.2967/jnumed.124.268956

Vancouver

Brumberg J, Schröter N, Blazhenets G, Omrane MA, Volz C, Weiller C, et al. [ 18 F]Florzolotau PET for the Differential Diagnosis of Parkinsonism in Patients with Suspected 4-Repeat Tauopathies. Journal of Nuclear Medicine. 2025;66(6):926-931. doi:10.2967/jnumed.124.268956

BibTeX
@article{Brumberg2025,
  author = {Brumberg, Joachim and Schröter, Nils and Blazhenets, Ganna and Omrane, M Aymen and Volz, Christian and Weiller, Cornelius and Rijntjes, Michel and Frings, Lars and Hellwig, Sabine and Jost, Wolfgang H and Meyer, Philipp T},
  title = {[ 18 F]Florzolotau PET for the Differential Diagnosis of Parkinsonism in Patients with Suspected 4-Repeat Tauopathies},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  volume = {66},
  number = {6},
  pages = {926--931},
  doi = {10.2967/jnumed.124.268956}
}
Kostenlos starten →